Article: Pharma Analysis & QC – Analytix Reporter special edition
Posted: 20 April 2020 | Merck | No comments yet
Biologics continue to be a major modality in the pharmaceutical pipeline. New and unique LC-MS tools will become available for use from discovery through QC.
Some of the characterization of biologics being performed in the LC-MS lab include intact mass, glycan analysis, peptide mapping, impurity and degradant identity, as well as bioanalytical assays for DMPK purposes. Beyond the capabilities of the mass spectrometer, consumables suppliers are now introducing novel sample preparation tools together with isotopically labeled and certified reference standards for the biologics market.
Subscribe here to receive your copy of Analytix Reporter
Download your PDF copy of Analytix Reporter
Related content from this organisation
- MSD set to acquire novel antibody for B-cell malignancies
- Novel immunotherapy combination approved for endometrial cancer
- Innovating small molecule injectables: market forecast to 2033
- Ophthalmology acquisition to advance tri-specific antibody
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Labelling, Manufacturing, Packaging, QA/QC, Regulation & Legislation, Research & Development (R&D)